UNSPSC 51342300: Antiviral guanines

Antiviral drugs made from purine bases related to hypoxanthine, an intermediate product of uric acid synthesis and a breakdown product of adenine catabolism.

UNSPSC 51342300 Antiviral guanines, a Class code, shows minimal alignment between its nominal scope and the state and local opportunities recently posted under it. The recent solicitations capture pharmaceutical procurement spanning naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing — none of which are antiviral guanines in the pharmaceutical chemistry sense. The code's current use appears to reflect either broad tagging of pharmaceutical and health-supply procurement by state and local issuing offices or a mismatch between the code's technical name and how procurement systems classify purchased goods. Issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), municipal fire and rescue services (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The mix reflects health department, emergency response, and state pharmacy benefit program procurement rather than a concentrated buyer base.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually for community health delivery; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for medical and first aid supplies to the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a 5 percent SLBE bid discount not to exceed $10,000; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) for vendor capabilities regarding direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with evaluation weighted heavily toward price competitiveness (75 percent). The code shows recent activity but limited coherence around a single product or service family.